相较于公司于 2025 年 11 月 29 日披露的《上海奥浦迈生物科技股份有限公 司发行股份及支付现金购买资产并募集配套资金报告书（草案）（上会稿）》，《重 组报告书》（注册稿）涉及的主要修订内容具体如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司（以 下简称"澎立生物"或"标的公司"）100.00%股权（以下简称"本次发行股份及 支付现金购买资产"），并向不超过 35 名特定投资者发行股票募集配套资金（以 下简称"本次募集配套资金"，与本次发行股份及支付现金购买资产合称"本次 交易"）。 上海证券交易所并购重组审核委员会（以下简称"上交所重组委"）于 2025 年 12 月 8 日召开 2025 年第 20 次并购重组审核委员会审议会议，对公司本次交 易的申请进行了审议。根据上交所重组委发布的《上海证券交易所并购重组审核 委员会 2025 年第 20 次审议会议结果公告》，本次会 ...

Core Viewpoint - Aopu Mai's asset acquisition application has been approved by the Shanghai Stock Exchange's M&A Committee, marking the first A-share market project to utilize a phased payment mechanism for share-based acquisitions since the introduction of the "Six Merger Guidelines" [1] Group 1: Transaction Details - Aopu Mai is primarily engaged in the research and production of cell culture media and provides CDMO services, while the target company, Pengli Bio, focuses on preclinical research services in drug and device development [1] - Upon completion of the transaction, the target company will become a wholly-owned subsidiary of the listed company, enhancing profitability and core competitiveness through synergistic effects [1] Group 2: Policy Implications - The approval of Aopu Mai's restructuring project exemplifies the implementation of the "Six Merger Guidelines" and highlights the policy direction to strengthen the resource allocation function of mergers and acquisitions [1] - The phased payment mechanism for share-based acquisitions enhances payment flexibility and better safeguards the interests of the listed company, allowing for adjustments in share payments based on the target company's operational performance [1] Group 3: Private Equity Involvement - The "reverse linkage" mechanism encourages private equity funds to participate in mergers and acquisitions by linking the investment period with the lock-up period for shares acquired through restructuring [2] - Private equity funds that have held shares in the target company for over 48 months will have a lock-up period of 6 months for shares obtained through this restructuring, promoting a "patient capital" approach [2] - The implementation of the "Six Merger Guidelines" and related policies has led to various measures such as mergers and acquisitions among peer companies and phased payment mechanisms, further supporting economic transformation and high-quality development [2]

中国经济网北京12月9日讯奥浦迈(688293.SH)昨日晚间披露公告，上海证券交易所并购重组审核委员会2025年第20次审议会议 于12月8日召开，审议结果显示，公司发行股份购买资产符合重组条件和信息披露要求。本次交易尚需经中国证券监督管理委 员会同意注册后方可实施。本次交易能否完成注册以及最终取得完成注册的时间均存在不确定性。 重组委会议现场问询的主要问题： 1.请上市公司代表结合上市公司和标的公司业务布局、目前主要收入覆盖疾病领域、境内外收入结构差异等，说明协同效应的 实现方式以及风险揭示的充分性。请独立财务顾问代表发表明确意见。 2.请上市公司代表结合境外市场药物临床前CRO业务的市场竞争格局、标的公司的竞争优劣势、境外销售资源投入、客户结构 等情况，说明标的公司境外销售收入确认的合规性以及预测期境外业务增长的可持续性。请独立财务顾问代表、会计师代表和 评估师代表发表明确意见。 需进一步落实事项： 截至2025年6月30日，上市公司总股本为113,548,754股。上市公司控股股东为肖志华，实际控制人为肖志华、HEYUNFEN(贺 芸芬)夫妇。肖志华直接持有上市公司24.92%股份，肖志华、HEYUN ...

Group 1 - Honghua Digital intends to acquire 49% equity of Shandong Yingkejie for 105 million yuan, resulting in full ownership of the company, which specializes in industrial inkjet technology [1] - Xue Ren Group's metal plate fuel cell stack project has passed final acceptance, delivering complete technical documentation and meeting performance requirements [2] - PIANO's controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [3] Group 2 - COSCO SHIPPING Specialised Carriers plans to invest 258 million yuan in Shenshan Port Investment Company, acquiring a 20% stake [4] - Jieshun Technology has won a management project for an underground parking lot, expecting over 70 million yuan in revenue by the end of the contract in 2031 [5] - Aerospace Rainbow is collaborating with Zhongtian Rocket to establish a company focused on artificial weather modification technology with a total investment of 50 million yuan [6] Group 3 - Purun Co. intends to acquire 49% equity of Nuoya Changtian through a combination of shares, convertible bonds, and cash, making it a wholly-owned subsidiary [7] - Dongfang Yuhong plans to sell a commercial property for 10.12 million yuan, expecting a significant asset disposal loss [8] - Tianqi Lithium is applying for designated delivery warehouse qualifications for lithium hydroxide at the Guangzhou Futures Exchange [9] Group 4 - Tianfu Communication is planning to issue H-shares on the Hong Kong Stock Exchange, with details yet to be finalized [10] - ST Yishite's controlling shareholder will transfer 4.18 million shares to Hubei Jingjiang Industrial Investment Group, changing the actual controller to the Jingzhou State-owned Assets Supervision and Administration Commission [11] - Dongwei Technology's directors and key technical personnel plan to reduce their holdings by up to 1.11% of the company's shares [12] Group 5 - Guojin Securities shareholders plan to reduce their holdings by a total of 0.72% of the company's shares [23] - Hongde Co. controlling shareholder and associated parties plan to reduce their holdings by up to 3% [24] - Aopu Mai's restructuring plan to acquire 100% of Pengli Bio has been approved by the exchange [26] Group 6 - Kosen Technology intends to sell 100% of Kosen Medical for 915 million yuan due to challenges in its business environment [28] - Rongsheng Petrochemical's subsidiary plans to transfer 100% of Rongsheng Energy (Zhoushan) to Rongsheng Holdings [29] - Jingji Zhino reported a cumulative sales revenue of 3.464 billion yuan from pig sales in the first 11 months of 2025 [30]

在重组委会议上，上交所重组委要求奥浦迈结合公司和澎立生物业务布局、目前主要收入覆盖疾病领 域、境内外收入结构差异等，说明协同效应的实现方式以及风险揭示的充分性。 此外，上交所重组委要求奥浦迈结合境外市场药物临床前CRO业务的市场竞争格局、标的公司的竞争 优劣势、境外销售资源投入、客户结构等情况，说明标的公司境外销售收入确认的合规性以及预测期境 外业务增长的可持续性。 北京商报讯（记者 丁宁）12月8日晚间，奥浦迈（688293）发布公告称，上海证券交易所并购重组审核 委员会（以下简称"上交所重组委"）于12月8日召开2025年第20次并购重组审核委员会审议会议，对公 司本次交易的申请进行了审议。本次会议的审议结果为：本次交易符合重组条件和信息披露要求。 据了解，奥浦迈拟通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司（以下简 称"澎立生物"）100%股权，并向不超过35名特定投资者发行股票募集配套资金。 ...

上海奥浦迈生物科技股份有限公司 关于发行股份及支付现金购买资产并募集配套资金事 项获得上海证券交易所并购重组审核委员会审核通过 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司（以 下简称"澎立生物"或"标的公司"）100.00%股权（以下简称"本次发行股份及 支付现金购买资产"），并向不超过 35 名特定投资者发行股票募集配套资金（以 下简称"本次募集配套资金"，与本次发行股份及支付现金购买资产合称"本次 交易"）。 公司将根据本次交易具体的进展情况，严格按照相关法律法规的规定和要求 证券代码：688293 证券简称：奥浦迈 公告编号：2025-112 及时履行信息披露义务，有关信息均以公司指定信息披露媒体和上海证券交易所 网站（www.sse.com.cn）发布的公告为准。敬请广大投资者注意投资风险。 上海证券交易所并购重组审核委员会（以下简称"上交所重组委"）于 2025 年 ...

人民财讯12月8日电，奥浦迈(688293)12月8日公告，公司拟通过发行股份及支付现金方式购买澎立生物 100%股权并募集配套资金(简称"本次交易")。上交所重组委于12月8日召开2025年第20次并购重组审核 委员会审议会议，对公司本次交易的申请进行了审议，审议结果为：本次交易符合重组条件和信息披露 要求。 ...

奥浦迈公告称，公司拟发行股份及支付现金购买澎立生物100%股权并募集配套资金。2025年12月8日， 上交所重组委召开会议审议该交易申请，结果为符合重组条件和信息披露要求。本次交易尚需经中国证 监会同意注册后方可实施，最终能否完成注册及完成时间存在不确定性。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Group 1 - The CRO index experienced a decline, with Aopumai leading the drop at 8.46% [1] - Other companies such as Medisi, Bideli Pharmaceutical, Chengdu Xian Dao, and Tigermed also saw declines of 3.72%, 3.16%, 2.74%, and 2.25% respectively [1]